Shionogi to acquire U.S. biopharmaceutical company IntraBio for ¥315.5 billion

Shionogi announced the acquisition of all shares in U.S. biopharmaceutical company IntraBio. The purchase price is ¥315.5 billion, and the transaction will proceed through Shionogi Inc.

Full text unavailableWorking from the headline and excerpt

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

Shionogi announced the acquisition of all issued shares of IntraBio through its U.S. group company, Shionogi Inc.

The purchase price is ¥315.5 billion, and the target is IntraBio, based in Texas, United States.

The transaction is expected to transfer IntraBio's shares to the Shionogi group. Details of the deal and its completion date remain subject to further announcements.

At a glance

EventShionogi announces acquisition of all IntraBio shares

AmountOffers ¥315.5 billion for the acquisition

TargetIntraBio (Texas, United States)

Lead partyThe acquisition will be carried out by Shionogi Inc.

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

ReutersNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.